139 related articles for article (PubMed ID: 22231687)
1. Prices gone wild: grey market 'scalpers' scoring windfall in American drug market.
Woodward C
CMAJ; 2012 Feb; 184(2):E119-20. PubMed ID: 22231687
[No Abstract] [Full Text] [Related]
2. Plenty of green in gray market. There's more at issue than just inflated prices for drugs in short supply.
May D
Mod Healthc; 2011 Oct; 41(42):25. PubMed ID: 22049782
[No Abstract] [Full Text] [Related]
3. How insurers' bargaining power affects drug prices in Medicare Part D.
Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
[No Abstract] [Full Text] [Related]
4. Prescription drug prices in the US.
Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
[No Abstract] [Full Text] [Related]
5. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
6. Public research funding and pharmaceutical prices: do Americans pay twice for drugs?
Conti RM; David FS
F1000Res; 2020; 9():707. PubMed ID: 33204410
[TBL] [Abstract][Full Text] [Related]
7. Shades of gray. Secondary drug distributors raise questions.
Lee J
Mod Healthc; 2011 Oct; 41(41):10, 12. PubMed ID: 22111494
[No Abstract] [Full Text] [Related]
8. Rebates-The Little-Known Factor Behind Increasing Drug List Prices.
Rubin R
JAMA; 2020 Mar; 323(9):812-813. PubMed ID: 32125400
[No Abstract] [Full Text] [Related]
9. US lawmakers seek cuts in prescription drug prices.
Jaffe S
Lancet; 2019 Mar; 393(10175):975-976. PubMed ID: 30860040
[No Abstract] [Full Text] [Related]
10. Regulating Drug Prices while Increasing Innovation.
Conti RM; Frank RG; Gruber J
N Engl J Med; 2021 Nov; 385(21):1921-1923. PubMed ID: 34767322
[No Abstract] [Full Text] [Related]
11. Running short.
Mettner J
Minn Med; 2011 Oct; 94(10):8-10. PubMed ID: 23256277
[No Abstract] [Full Text] [Related]
12. Prescription-drug coupons--no such thing as a free lunch.
Ross JS; Kesselheim AS
N Engl J Med; 2013 Sep; 369(13):1188-9. PubMed ID: 23984672
[No Abstract] [Full Text] [Related]
13. How to Reduce Prescription Drug Prices: First, Do No Harm.
Atlas S
Mo Med; 2020; 117(1):14-15. PubMed ID: 32158034
[No Abstract] [Full Text] [Related]
14. Policy Recommendations for Pharmacy Benefit Managers to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians.
Daniel H; Bornstein SS;
Ann Intern Med; 2019 Dec; 171(11):823-824. PubMed ID: 31711103
[TBL] [Abstract][Full Text] [Related]
15. Recent Trends in Prescription Drug Launch Prices-Reply.
Rome BN; Egilman AC; Kesselheim AS
JAMA; 2022 Oct; 328(13):1352-1353. PubMed ID: 36194222
[No Abstract] [Full Text] [Related]
16. The Economics of Indication-Based Drug Pricing.
Chandra A; Garthwaite C
N Engl J Med; 2017 Jul; 377(2):103-106. PubMed ID: 28700848
[No Abstract] [Full Text] [Related]
17. Laws fail to slow gray market. Concerns raised over secondary drug distributors.
Lee J
Mod Healthc; 2011 Oct; 41(40):14. PubMed ID: 22049854
[No Abstract] [Full Text] [Related]
18. Trends in Prescription Drug Launch Prices, 2008-2021.
Rome BN; Egilman AC; Kesselheim AS
JAMA; 2022 Jun; 327(21):2145-2147. PubMed ID: 35670795
[TBL] [Abstract][Full Text] [Related]
19. Analysis of State-Level Drug Pricing Transparency Laws in the United States.
Ryan MS; Sood N
JAMA Netw Open; 2019 Sep; 2(9):e1912104. PubMed ID: 31553467
[TBL] [Abstract][Full Text] [Related]
20. Determinants of Market Exclusivity for Prescription Drugs in the United States.
Kesselheim AS; Sinha MS; Avorn J
JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
